Market capitalization | $435.64m |
Enterprise Value | $300.13m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 6.58 |
P/S ratio (TTM) P/S ratio | 9.55 |
P/B ratio (TTM) P/B ratio | 2.04 |
Revenue growth (TTM) Revenue growth | 19.85% |
Revenue (TTM) Revenue | $45.60m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a MaxCyte Inc forecast:
8 Analysts have issued a MaxCyte Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 46 46 |
20%
20%
|
|
Gross Profit | 35 35 |
19%
19%
|
|
EBITDA | -42 -42 |
2%
2%
|
EBIT (Operating Income) EBIT | -46 -46 |
1%
1%
|
Net Profit | -36 -36 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Gaithersburg, MD.
Head office | United States |
CEO | Maher Masoud |
Employees | 143 |
Founded | 1998 |
Website | www.maxcyte.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.